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Abstract
The new risk-factors for peptic ulcers induced by the use of nonsteroidal antiinflammatory drugs, such as polymorphism 
of different isoenzymes of cytochrome P450 were considered in the article. The aim of the research was to study different genetic 
polymorphism of several ferments CYP2C9 and CYP2C19 in inclination to NSAIDS-gastropathies by the way of estimation the risk 
of appearance of Helicobacter pylori (HP)-positive or Hp-negative NSAIDS- induced peptic ulcers, complicated or not with upper 
gastrointestinal bleeding.
124 persons were examined (76 men, 48 women in the age of 56,2+/–9,1 years) with Hp-positive or Hp-negative NSAIDS-induced 
peptic ulcers, that were performed genotyping of isoferments of cytochrome system (CYP2C9, CYP2C19). Based on investigations of 
5 different isoenzymes (CYP 2C9*2, CYP 2C9*3, CYP 2C19*2, CYP 2C19*3 and CYP 2C19*17). It was founded that peptic ulcers 
are strictly associated only with CYP 2C19*17-genotype, possibly due to its involvement in arachidonic acid metabolism and gastro-
protection. Thus, polymorphism CYP 2C19*17 can be considered as one of the risk factors for NSAID-gastropathy though the future 
researches are needed.
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1. Background
Nonsteroidal anti-inflammatory drugs (NSAIDs)-is one of highly used drugs, taken by 
30 million of people every day.
The popularity and high use of NSAIDs is explained by their significant analgetic and 
anti-inflammatory effect in treatment of arthritis and other acute or chronic diseases of musclo-
skeletal system and pain syndroms of differnet genesis [1–3]. Un fortunately, use of NSAIDs is 
essentially restricted because of adverse effects (AE), such as gastropathyes, firstly.
NSAIDs-gastropathies are erosive ulcerative affects of gastroduodenal zone, that appear 
during the use of NSAIDs and aspirin and have a specific cilinic an endoscopic picture.Their di-
agnostic criteries are chronologic connection with the usage of NSAIDs, the lack of symptoms, 
blurring clincal picture, the high risk of bleeding manifistation, acute and often numerous injuries, 
preferred location in antral part of a stomach, the absence of inflammatory wave around the ulcers, 
foveolar hyperplasia of mucose and quite quick healing, when NSAIDs cancelled. Gastroduodenal 
toxity is explained by the block of production of cytoprotective prostanoids, intermediated with the 
1st type of cyclooxygenase, such as prostaglandin E2 and prostacyclin. High selective ingibitors 
of the 2nd type of cyclooxygenase provoke less expressed injuries of gastroduodenal zone, than 
non-selective NSAIDs, that inhibit the 1st type of cyclooxygenase and the 2nd type of cyclooxy-
genase as well. But they don’t solve the hole problem [4–6].
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This problem is extremely actual, as long as the number of hospatalisations and deathes, 
connected with the usage of NSAIDs and economical expenses for curing NSAIDs-gastropathies 
grow every year. Ulcers and bleeding, inducted with the usage of NSAIDs still remain one of the 
most important problems of the internal medicine. Thus, for the information from the different 
sorces, near 25–40 % of chronic users of NSAIDs have got erosion and peptic ulcers of gastro-
duodenal zone. And 2–4 % of patients have got bleedings and perforations, that cause bad effect. 
Rick related bleeding manifstation , perforation and death as a result of NSAIDs-induced ulcers 
made accordingly 3,6 and 7,6 [2, 6]. The states, connected with the usage of NSAIDs make a great 
contribution in common number of morbidity and mortality in many contries all over the world. For 
example, in USA adverse effects of the usage of NSAIDs are the 15th often cause of mortality. And 
in common, 30 % of patients, taking NSAIDs have got gastrointestinal AE even if ulcers are ab-
sent. In Great Britain among 18000 of hospitalised patients NSAIDs were the main class of drugs, 
casing AE (in 30 % of patients), and NSAIDs-induced ulcers and bleedings were the cause of 61 % 
of deathes, connectsd to AE of drugs [6].
Ulcerous anamnesis( relative risk=13,5), usage of several NSAIDs, including aspirin (rel-
ative risk= 9,0), usage of high doses of NSAIDs (relative risk=7,0), usage of anticoagulants (rela-
tive risk=6,4), age under 70 (relative risk=5,6), usage of corticosteroids (relative risk=2,2), Heli-
cobacter pylory infection (Hp) are used to be generally acknowledged as a risk of development of 
gastropathies [2, 7–9]. Unfortunately, many other factors of risk,that influence an appearance of 
NSAIDs-gastropathies are not well learned, because of inconsistent information from differant 
sources of information. In particular, terms of appearance of gastrointestinal AE and complica-
tions, farmakokinetics of used NSAIDs, and what part of gastrointestinal tract is mostly affected, 
frequency of AE development in different rheumathologic pathology, consequences of usage of 
NSAIDs with a long period of excretion( retard forms). There are only several works about fre-
quency and evidence AE of usage of NSAIDs and the effectiveness of therapy according to poly-
morphism of different isoenzymes of hepatic cytochrome P450 (CYP2C8, CYP2C9, CYP2C19) 
system, that is responsible for metabolism of many drugs [10–14].
The family of cytochrome CYP2C includes 20 % of hepatic maintenance of CYP450 and 
metabolises 25–30 % of often used drugs such as NSAIDs, Inhibitors of proton pomp (IPP), antide-
pressants, benzodiasepines and clopidogrel [1, 15–18]. It’s important, that isoenzymes CYP2C also 
metabolise endogenous substance, such as arachidonum acid and estrogens [19]. Three represen-
tatives of the family CYP2C (CYP2C8, CYP2C9, CYP2C19) are highly polymorphic isoenzymes 
and have numerous mononucleotide polymorphism (MNP) with different frequency in different 
ethnic populations [20–22]. Today 14 CYP2C8-, 35 CYP2C9-, 28 CYP2C19-coding (MNP) are 
well known, some of which are clinically important, as they can essentially change metabolism of 
different drugs. 
Previous researches showed people with MNP in genes, coding enzymes that metabo-
lise NSAIDs, to have a higher risk of development of peptic ulcers and/or upper gastrointesti-
nal bleeding (GIB), although the results were quite disputable [1, 6, 10, 11, 16, 23]. Performed 
systematic review on this problem showed, that in presence it’s very difficult to evaluate if 
there is an interaction between effects of NSAIDs and presence of coding variants of basic 
NSAIDs-metabolising systems of cytochrome P450, such as CYP2C9, CYP2C8, CYP2C19 
and also if these variants raise the risk of NSAIDs-gastropathies development not depending 
on each other [10–14].
Quite recently MNP in family CYP2C19 (CYP2C19*17) was detected to cause inclination 
to appearance of peptic ulcers by the way of changing of IPP metabolism [16, 18, 24, 25].
2. The aim of research
To study the different genetic polymorphism of several enzymes CYP2C9 and CYP2C19 
in inclination to NSAIDS-gastropathies by the way of estimation of possible connection between 
some clinically important MNP and the risk of appearance of Helicobacter pylori (HP)-positive or 
Hp-negative NSAIDS- induced peptic ulcers, complicated or not with the upper GIB .
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3. Materials and methods
124 persons were examined (76 men, 48 women in the age of 56,2+/–9,1 years old) with 
Hp-positive or Hp-negative NSAIDS-induced peptic ulcers, that underwent genotyping of isoen-
zymes of cytochrome system (CYP2C9, CYP2C19). All patients underwent upper endoscopy and 
detection of HP-status with the help of 13C-urea test.
All patients were divided into 2 groups: 
1) patients with endoscopy proved peptic ulcers (64 person), appeared during 2 weeks-in-
take of NSAIDS; 
2) patients without peptic ulcers (60 person, that either take NSAIDS (38 person), or not 
(22 person) before endoscopy. 
To NSAIDS-users were ascribed people, who take this medicine at least for a week or 
more in period of 2 weeks before endoscopy.
Among 124 patients peptic ulcers were endoscopy verified in 64 patients ( 51,6 %), includ-
ing 82,3 % of patients with NSAIDS intake and 17,7 % of patients without it. And 60 patients 
(48,4 %) didn’t have any endoscopy substantiation of peptic ulcers (63,3 % of them take NSAIDS 
and 36,7 % didn’t) . Among the patients with peptic ulcers 20 patients (31,3 %), with NSAIDS-in-
take and 4 (6,6 %) ones had upper GIB. 81,3 % patients with peptic ulcers and 66,6 % person 
without them were Hp-infected. There are clinical and demographic characteristics of patients 
with peptic ulcers (PU) or without them in Table 1.
Table 1
Clinical and demographic characteristic of patients.
Characteristics Patients with PU (n=64) Patients without PU (n=60)
Average age (+/–) 53.1 (7.8) 58.3 (7.5)
Men, n (%) 46 (71.9) 30 (50)
Endoscopic indication, n (%)
Melena 
Dispeptic syndrome/ abdominal pain
Anemia
Reflux symptoms
Others
20 (31.1 %)
25 (39.1 %)
12 (15.6 %)
5 (4.9 %)
2 (3.1 %)
2 (3.3 %)
28 (46.6 %)
6 (10 %)
12 (20 %)
12 (20 %)
Hp+, n (%) 52 (81.3 %) 41 (66.6 %)
Smoking, n (%) 31 (46.8 %) 26 (43.3 %)
Alcohol abuse, n (%) 14 (21.9 %) 11 (18.3)
NSAIDS-intake
Low doze of aspirin
Diclofenac
Ibuprofen
Coxibes
64 (100 %)
23 (35.9 %)
25 (39.1 %)
2 (4.7 %)
13 (20.3 %)
38 (63.3 %)
12 (31.6 %)
14 (36.8 %)
5 (13.2 %)
7 (18.4 %)
Concomitant therapy, n (%)
IPP
Antitrombocyte medicines
Steroids 
48 (75 %)
12 (18.8 %)
4 (63 %)
7 (11.7 %)
3 (5 %)
1 (1.7 %)
Clinical anamnesis, n (%)
Duodenal ulcer 
Gastric ulcer
GIB
Cardiovascular pathology
Cerebrovascular pathology
Respiratory diseases
Muscle and skeletal problems
Diabetes
11 (17.2 %)
4 (6.3 %)
8 (12.5 %)
22 (34.4 %)
17 (26.6 %)
6 (9.4 %)
12 (18.8 %)
5 (7.8 %)
7 (11.7 %)
1 (1.7 %)
2 (3.4 %)
21 (35 %)
18 (30 %)
5 (8.3 %)
10 (16.6 %)
5 (8.3 %)
Genotyping was performed after separation of genome DNA from the solid blood with addi-
tion of EDTA with the help of multiplex polymerase chain reaction (PCR) with fluorescent scheme 
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of detection of products in Real time “SNP-EXPRESS-SHOT” – PB with the use of test-systems 
LOTECH CYP2C9 and CYP3C19 ACE (S. Petersburg, Russian). According to the data of genotyp-
ing, such variants of polymorphism of cytochrome CYP2C9 were detected: CYP2C9*2 (rs 1799853) 
and CYP2CP*3 (rs1057910), and also such variants of polymorphism of cytochrome 2C19 as CY-
P2C19*2 (rs4244285), CYP2C19*3 (rs4986893) and CYP2C19*17 (rs12248560). Depending on 
genotype 2C19 examined patients could be ascribed to the group of extremely fast metabolisers of 
IPP (genotype *1/*17), fast metabolisers of IPP (genotype *1/*1), moderately fast metabolisers of 
IPP (genotype *1/*2, *1/*3) or slow metabolisers of IPP (genotype *2/*2,*2/*3, *3/*3).
4. The results of research
According to the data of the Table 2, with the help of logistic regressive analysis, only one 
MNP, CYP2C19*17 appeared to be noticeably connected with PU (correlation of chance (CC)-1.45; 
95 % confidence interval (CI)-1.14 to 1.90; P=0.005). No positive connection between learned CY-
P2C-genotypes and NSAIDS, also between H. pylori status (negative or positive) was found. Pos-
sibly because of not large excerpt of patients.
Table 2
Analysis of connection between learned polymorphisms of CYP2C9 and CYP2C19 and presence 
of peptic ulcers
MNP Reference MNP Analysis of connection with presence of PU
n P CC 95 % CI
CYP2C9*2 rs1799853 124 0.83 0.96 0.69–1.35
CYP2C9*3 rs1057910 122 0.76 0.94 0.63–1.40
CYP2C19*2 rs4244285 123 0.91 1.02 0.74–1.41
CYP19*3 rs4986893 123 0.86 0.92 0.71–1.36
CYPC19*17 rs12248560 122 0.005 1/45 1.14–1.90
 
A big part of patients with PU was notified among carriers of variant allele CYP2C19*17 
(1*/17–71,7 %; 17*/17*–21,9 %, variants CT and TT accordingly comparatively to homozygotes 
of such type (1*/1*–6,4 %; P=0,024 with the use of X2n text). Analysis of sensitivity, that was 
performed in patients without Hp-infection, didn’t show the confident connection with genotype 
CYP2C19*17 comparing with patients with or without PU (P=0.062) or patients with or without 
upper GIB (P=0,63).
5.  Discussion of results
Unlike the other previous researches in our work, we have studied the role of five different 
genetic polymorphisms of isoenzymes CYP2C9 and CYP2C19 in inclination to NSAIDS-gastrop-
athies, particularly to development of NSAIDS-induced peptic ulcers and upper GIB. The received 
results didn’t show any connection between polymorphism CYP2C9*2, CYP2C9*3, CYP2C19*2, 
CYP2C19*3 and NSAIDS-induced peptic ulcers and upper GIB. Nevertheless, we’ve noticed con-
nection between the allele of CYP2C*17 and presence of PU in all allele and genotype levels, 
independently on affect of NSAIDS and the presence of Hp-infection. The further analysis, taking 
into account all of CYP2C19-genotypes and the presence of PU (with the use of genotype *1/*1 as 
initial base) showed only genotype *1/*17 to be connected to PU noticeably.
Why CYP2C19*17 is connected to Pu isn’t clear enough, although there are several expla-
nations. As CYP2C19*17 is known to be a spread polymorphism with amplification of function, 
carriers of which have a higher index of metabolism of some clinically important medicines (such 
as IPP, escitolopram, sertrallin, clopidogrel and other), with further decrease of their concentration 
in plasma and extenuation of clinical effect [7, 15, 16, 18, 20, 24, 26–30]. Nevertheless, the review 
of functional and clinical consequences of carrying of allele CYP2C19*17 made a conclusion, that 
it has only insignificant effect, that hardly would be clinically important, besides homozygotes 
CYP2C19*17, and only for medicines with narrow therapeutic window [18, 24, 28]. On the other 
hand, there were made conclusion in some recent researches, that carrying of allele CYP2C19*17 
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in patients, taking clopidogrel is associated with lower reactivity of thrombocytes, decrease of the 
risk of cardiovascular diseases and thrombosis of the stent, but with the higher risk of intensive 
bleedings [30, 31]. So one of the possible explanation of noticed connection may be the fact, that 
carriers of CYP2C19*17 accelerate metabolism and decline clinical effectiveness of IPP, and de-
cline gastroprotective possibility of mucosa to resist to aggressive factors( for example, NSAIDS 
and H. pylori) and incline to appearance of PU in that way.
Besides, isoenzymes CYP2C take part not only in metabolism of xenobiotics, but different 
endogen substances [18, 21, 22]. For example, arachidonic acid in 4 types epoxyeikosatrien acids 
(EETA)-5,6-EETA, 8,9-EETA, 11-12-EETA and 14,15-EETA, that are known to be species and 
organ specific and have different physiological functions ( including control of vascular tonus, 
angiogenesis, migration of cells, proliferation and inflammation) [19]. Although, the role of EETA 
in human gastrointestinal tract isn’t studied thoroughly, they are considered to inhibit production 
of prostoglandine E2 in the cells of unstriated muscles and take part in formation of active forms 
of oxygen in endothelial cells of vessels, that can cause ischemic dysfunctions [19, 23, 25]. So one 
of the possible explanations of the connection between PU and CYP2C19*17 can be that the last 
one changes metabolism of arachidonic acid, and as a result, protective features of Gastroduodenal 
mucosa decrease because of lower rate of production of gastroprotective prostaglandine E2 and 
amplification of vasoconstriction in microcirculatory circle of mucosa and production of active 
damaging forms of oxygen [25, 32]. 
6. Conclusion
So, our research showed, that the presence of allele CYP2C19*17 has confident connection 
with endoscopic proved NSAIDS-induced PU and may be considered as a factor of the risk of 
NSAIDS-gastropathy development. Possible biological explanation of the found association may be 
participation of isoenzyme CYP2C19 in metabolism of arachidonic acid that is known to take part 
in gastroprotection and pathogenesis of PU. Patients with polymorphism CYP2C19 have not only 
the higher risk of development of NSAIDS-induced peptic ulcers, but faster metabolism of IPP, 
that significantly decrease their clinical effectiveness and make healing of ulcers lower. To prove 
our conclusions and more deeply estimate functional consequences about affect of polymorphism 
CYP2C19*17 on pathogenesis of PU, further researches in different populations and with more 
quantity of patients should be done.
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